telephone (318) 356–7444, or email at ncptt@nps.gov.

FOR FURTHER INFORMATION CONTACT: Kirk

A. Cordell, via telephone (318) 356—7444. Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.

#### SUPPLEMENTARY INFORMATION:

Established within the Department of the Interior, the National Center for Preservation Technology and Training (Center) is located at Northwestern State University of Louisiana in Natchitoches, Louisiana. Title IV, section 404 of Public Law 102–575, October 30, 1992, established the Board to provide advice and professional oversight to the Secretary of the Interior and the Center regarding the activities of the Center and to submit an annual report to the President and the Congress.

The Board is comprised of 13 representative members appointed for 4year terms, as follows: (a) one member serving as the Secretary's designee; (b) six members who represent appropriate Federal, State, and local agencies, State and local historic preservation commissions, and other public and international organizations; and (c) six members on the basis of outstanding professional qualifications who represent major organizations in the fields of archeology, architecture, conservation, curation, engineering, history, historic preservation, landscape architecture, planning, or preservation education.

We are currently seeking members on the basis of outstanding professional qualifications who represent major organizations in the fields of archeology, architecture, conservation, curation, engineering, history, historic preservation, landscape architecture, planning, or preservation education. Nominations should be typed and should include a resume providing an adequate description of the nominee's qualifications, including information that would enable the Department of the Interior to make an informed decision regarding meeting the membership requirements of the Board and permit the Department of the Interior to contact a potential member. All documentation, including letters of recommendation, must be compiled and submitted in one complete package. All those interested in membership, including current members whose terms are expiring,

must follow the nomination process. Members may not appoint deputies or alternates.

Members of the Board serve without compensation. However, while away from their homes or regular places of business in the performance of services for the Board as approved by the NPS, members may be allowed travel expenses, including per diem in lieu of subsistence, in the same manner as persons employed intermittently in Government service are allowed such expenses under section 5703 of title 5 of the United States Code.

Authority: 5 U.S.C. 10.

## Alma Ripps,

Chief, Office of Policy.

[FR Doc. 2023-02121 Filed 2-1-23; 8:45 am]

BILLING CODE 4312-52-P

# INTERNATIONAL TRADE COMMISSION

[USITC SE-23-009]

# **Sunshine Act Meetings**

**AGENCY HOLDING THE MEETING:** United States International Trade Commission. **TIME AND DATE:** February 8, 2023 at 9:30 a.m.

**PLACE:** Room 101, 500 E Street SW, Washington, DC 20436, Telephone: (202) 205–2000.

**STATUS:** Open to the public.

# MATTERS TO BE CONSIDERED:

- 1. Agendas for future meetings: none.
- 2. Minutes.
- 3. Ratification List.
- 4. Commission vote on Inv. Nos. 701–TA–679 and 731–TA–1585 (Final) (Sodium Nitrite from India). The Commission currently is scheduled to complete and file its determinations and views of the Commission on February 20, 2023.
  - 5. Outstanding action jackets: none.

# **CONTACT PERSON FOR MORE INFORMATION:** Sharon Bellamy, Acting Supervisory Hearings and Information Officer, 202–205–2595.

The Commission is holding the meeting under the Government in the Sunshine Act, 5 U.S.C. 552(b). In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission: Issued: January 31, 2023.

# Katherine Hiner,

Acting Secretary to the Commission.
[FR Doc. 2023–02338 Filed 1–31–23; 4:15 pm]
BILLING CODE 7020–02–P

# INTERNATIONAL TRADE COMMISSION

[USITC SE-23-008]

## **Sunshine Act Meetings**

**AGENCY HOLDING THE MEETING:** United States International Trade Commission. **TIME AND DATE:** February 7, 2023 at 11:00

**PLACE:** Room 101, 500 E Street SW, Washington, DC 20436, Telephone: (202) 205–2000.

**STATUS:** Open to the public.

## **MATTERS TO BE CONSIDERED:**

- 1. Agendas for future meetings: none.
- 2. Minutes.
- 3. Ratification List.
- 4. Commission vote on Inv. No. 731– TA–1073 (Fifth Review) (Furfuryl Alcohol from China). The Commission currently is scheduled to complete and file its determinations and views of the Commission on February 15, 2023.
  - Outstanding action jackets: none.

# **CONTACT PERSON FOR MORE INFORMATION:** Sharon Bellamy, Acting Supervisory Hearings and Information Officer, 202–205–2595.

The Commission is holding the meeting under the Government in the Sunshine Act, 5 U.S.C. 552(b). In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission. Issued: January 30, 2023.

#### Katherine Hiner,

 $\label{eq:acting Secretary to the Commission.}$  [FR Doc. 2023–02247 Filed 1–31–23; 11:15 am]

BILLING CODE 7020-02-P

# **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

# Reynaldo De Los Angeles, M.D.; Decision and Order

On October 24, 2022, the Drug Enforcement Administration (hereinafter, DEA or Government) issued an Order to Show Cause (hereinafter, OSC) to Reynaldo De Los Angeles, M.D. (hereinafter, Registrant). Request for Final Agency Action (hereinafter, RFAA), Exhibit (hereinafter, RFAAX) 2 (OSC), at 1, 3. The OSC proposed the revocation of Registrant's Certificate of Registration No. FD5611365 at the registered address of 1617 W 39th Street, Ste. 1, Kearney, NE 68845–2713. *Id.* at 1. The OSC alleged that Registrant's registration

should be revoked because Registrant is "without authority to handle controlled substance[s] in Nebraska, the state in which [he is] registered with DEA." *Id.* at 2 (citing 21 U.S.C. 824(a)(3)).

The Agency makes the following findings of fact based on the uncontroverted evidence submitted by the Government in its RFAA dated December 20, 2022.<sup>1</sup>

# **Findings of Fact**

On October 5, 2022, the Nebraska Department of Health and Human Services (NDHHS) issued an Order temporarily suspending Registrant's Nebraska medical license based on Registrant's state criminal conviction from August of 2022.<sup>2</sup> RFAAX 3, Appendix A, at 1–4. On December 7, 2022, NDHHS issued an Order revoking Registrant's Nebraska medical license based on both his state criminal conviction and on his lengthy disciplinary history with NDHHS. RFAAX 3, Appendix B, at 1, 5–6; see also id. at 12–70

According to Nebraska's online records, of which the Agency takes official notice, Registrant's license is still revoked.<sup>3</sup> Nebraska Department of Health and Human Services License Information System Search, https://www.nebraska.gov/LISSearch/search.cgi (last visited date of signature of this Order). Accordingly, the Agency finds that Registrant is not licensed to engage in the practice of medicine in Nebraska, the state in which he is registered with the DEA.

#### Discussion

Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under section 823 of the Controlled Substances Act (hereinafter, CSA) "upon a finding that the registrant . . . has had his State license or registration suspended . . . [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances." With respect to a practitioner, the DEA has also long held that the possession of authority to dispense controlled substances under the laws of the state in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner's registration. See, e.g., James L. Hooper, M.D., 76 FR 71371 (2011), pet. for rev. denied, 481 F. App'x 826 (4th Cir. 2012); Frederick Marsh Blanton, M.D., FR 27616, 27617 (1978).4

According to Nebraska statute, "[d]ispense means to deliver a controlled substance to an ultimate user or a research subject pursuant to a medical order issued by a practitioner authorized to prescribe, including the packaging, labeling, or compounding necessary to prepare the controlled substance for such delivery." Neb. Rev. Stat. § 28-401(8) (2022). Further, a "[p]ractitioner means a physician . . or any other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe, conduct research with respect to, or administer a controlled substance in the course of practice or research in this state . . . ." Id. at § 28–401(21).

Here, the undisputed evidence in the record is that Registrant lacks authority to practice medicine in Nebraska. As

discussed above, a physician must be a licensed practitioner to dispense a controlled substance in Nebraska. Thus, because Registrant lacks authority to practice medicine in Nebraska and, therefore, is not authorized to handle controlled substances in Nebraska, Registrant is not eligible to maintain a DEA registration. Accordingly, the Agency will order that Registrant's DEA registration be revoked.

## Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. FD5611365 issued to Reynaldo De Los Angeles, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending applications of Reynaldo De Los Angeles, M.D., to renew or modify this registration, as well as any other pending application of Reynaldo De Los Angeles, M.D., for additional registration in Nebraska. This Order is effective March 6, 2023.

# **Signing Authority**

This document of the Drug Enforcement Administration was signed on January 25, 2023, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the Federal Register.

#### Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2023-02132 Filed 2-1-23; 8:45 am]

BILLING CODE 4410-09-P

## **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

# Dylan E. O'Connor, M.D.; Decision and Order

On September 15, 2022, the Drug Enforcement Administration (hereinafter, DEA or Government) issued an Order to Show Cause (hereinafter, OSC) to Dylan E. O'Connor, M.D. (hereinafter, Registrant). Request for Final Agency Action (hereinafter, RFAA), Exhibit (hereinafter, RFAAX) 1

<sup>&</sup>lt;sup>1</sup> Based on a Declaration from a DEA Diversion Investigator, the Agency finds that the Government's service of the OSC on Registrant was adequate. RFAAX 3, 2–3. Further, based on the Government's assertions in its RFAA, the Agency finds that more than thirty days have passed since Registrant was served with the OSC and Registrant has neither requested a hearing nor submitted a written statement or corrective action plan and therefore has waived any such rights. RFAA, at 2; see also 21 CFR 1301.43 and 21 U.S.C. 824(c)(2).

 $<sup>^2\,\</sup>rm Registrant's$  Nebraska medical license expired by its terms on October 1, 2022. RFAAX 3, Appendix F.

<sup>&</sup>lt;sup>3</sup> Under the Administrative Procedure Act, an agency "may take official notice of facts at any stage in a proceeding—even in the final decision. United States Department of Justice, Attorney General's Manual on the Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e), "[w]hen an agency decision rests on official notice of a material fact not appearing in the evidence in the record, a party is entitled, on timely request, to an opportunity to show the contrary." Accordingly, Registrant may dispute the Agency's finding by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and response shall be filed and served by email to the other party and to Office of the Administrator, Drug Enforcement Administration at dea.addo.attorneys@dea.gov.

<sup>&</sup>lt;sup>4</sup> This rule derives from the text of two provisions of the CSA. First, Congress defined the term "practitioner" to mean "a physician . . . or other person licensed, registered, or otherwise permitted, . . the jurisdiction in which he practices . . to distribute, dispense, . . . [or] administer . . . a controlled substance in the course of professional practice." 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner's registration, Congress directed that "[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices." 21 U.S.C. 823(f). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the CSA, the DEA has held repeatedly that revocation of a practitioner's registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the state in which he practices. See, e.g., James L. Hooper, 76 FR at 71371–72; Sheran Arden Yeates, M.D., 71 FR 39130, 39131 (2006); Dominick A. Ricci, M.D., 58 FR 51104, 51105 (1993); Bobby Watts, M.D., 53 FR 11919, 11920 (1988); Frederick Marsh Blanton, 43 FR at 27617.